Protein glycation, induced by hyperglycemia, is implicated in the appearance of diabetic complications and the aging process. Glycation involves the non-enzymatic reaction between sugars and protein amino groups that lead to formation of advanced glycation end products (AGEs). When aminoguanidine, a proven AGE inhibitor, was tested as an anti-diabetic drug in clinical trials showed critical side effects, which suggested a need for improved AGE inhibitors. A protein glycation model included histone H1 and glyoxal or methylglyoxal since it allowed to distinguish AGE inhibitors from...